Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Based on an average daily volume of 66,900 shares, the short-interest ratio is currently 0.8 days. Approximately 1.3% of the shares of the stock are sold short.
Analyst Ratings Changes
MNPR has been the subject of several research reports. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler began coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective for the company.
Read Our Latest Research Report on Monopar Therapeutics
Institutional Inflows and Outflows
Monopar Therapeutics Price Performance
MNPR stock traded up $3.19 during midday trading on Monday, hitting $32.94. The stock had a trading volume of 13,869 shares, compared to its average volume of 360,329. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market cap of $200.97 million, a PE ratio of -16.72 and a beta of 1.18. The company’s 50-day moving average price is $35.77 and its 200 day moving average price is $21.54.
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Further Reading
- Five stocks we like better than Monopar Therapeutics
- What is the S&P/TSX Index?
- The “Quality” Rotation: Back to Basics Investing
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Occidental Petroleum: 4 Reasons to Love These Prices
- How to Short a Stock in 5 Easy StepsĀ
- Super Micro’s International Presence Makes It a Winning Stock
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.